Objectives: Early target attainment is the key factor influencing the outcome of antimicrobial therapy. The objective of the present study was to evaluate the relationship between azithromycin concentrations during the first 24-48 h of therapy and the clinical outcome in order to optimize antimicrobial therapy.
Introduction
Azithromycin is the most widely used macrolide in children for the therapy of lower respiratory tract infections (LRTIs). 1, 2 It prevents the growth of bacteria by binding to the 50S subunit of the bacterial ribosome to interfere with the translation of mRNA. 3 Despite its wide use, azithromycin is still used in an off-label manner in paediatric patients, partly due to the lack of pharmacokinetic/pharmacodynamic data.
Early target attainment is the key factor influencing the outcome of antimicrobial therapy. The relationship between early appropriate therapy and enhanced survival has been well demonstrated. 4 Once an infection is highly suspected or confirmed, the first 24-48 h is the prime time for success of antimicrobial therapy. Failure to combat the causative pathogen adequately within this critical time frame clearly adds to the risk of mortality. 5 We hypothesized that early target attainment is the key factor for azithromycin treatment success in children. Thereby, the relationship between azithromycin concentrations during the first 24-48 h and clinical outcome was evaluated in the present study in order to optimize antimicrobial therapy.
Patients and methods

Study design
Children hospitalized with symptoms or signs of acute infection (e.g. fever), acute respiratory illness (e.g. cough) and radiographic evidence of LRTI who received azithromycin (10 mg/kg; maximum 500 mg once daily for 5-7 days) monotherapy were enrolled in the study. The study was conducted at the Beijing Children's Hospital during the period 2014-17. Demographic data, clinical characteristics, diagnosis of LRTIs and response to, or adverse events associated with, azithromycin therapy were recorded. Exclusion criteria included the following: history or evidence of chronic pathology of any organ system and incomplete clinical information.
Ethics
The study was approved by the Children's Hospital Ethics Committee (No. 2015-45). Written consent for participation in the study was obtained from the parents or legal guardians.
Measurement of azithromycin concentrations
To evaluate target attainment, azithromycin trough concentrations were collected within the first 2 calendar days of hospitalization and were determined using HPLC with tandem MS. The calibration curve ranged from 0.01 to 2.00 mg/L. The inter-and intra-day coefficients of variation of controls were 8.6% and 5.2%, respectively. The lower limit of quantification was 0.01 mg/L. Given the pharmacokinetic/pharmacodynamic characteristics of azithromycin, for effective bacterial eradication, a target trough concentration of 0.25 mg/L was selected to maintain the MIC that is required to inhibit 90% (MIC 90 ) of suspected pathogenic bacteria. 6 
Effectiveness assessments
The assessment of response to azithromycin therapy, as partial or complete, was based on clinical (signs and symptoms of infection, and inflammatory markers) and radiological (X-ray or CT findings) improvement or resolution and on proven or presumed eradication of the pathogen. Clinical effectiveness was defined as disappearance or subsidence of clinical signs and symptoms of infection, and/or improvement of inflammatory markers and radiological examinations within the treatment period. Lack of response to azithromycin therapy was defined as unchanged or worsened clinical signs and symptoms, inflammatory markers and radiological examinations after 5-7 days of treatment.
Safety assessments
Adverse events were recorded and classified as mild, moderate, severe or life-threatening. The relationship with treatment was recorded as possibly related, probably related, certainly related, probably not related or certainly not related. For liver injury events, all cases were graded for severity on a scale of 1-4, corresponding to mild, moderate, moderate/severe or severe using standardized criteria, as in Table 1 .
7,8
Statistical analysis
Proportions were compared by the v 2 test or Fisher's exact test, as appropriate. Continuous variables were compared by the t-test or Wilcoxon test, as appropriate. Statistical significance was defined by a two-sided P value ,0.05. The Spearman method was used to study the correlation of two variables. A logistic regression analysis was performed to analyse the association between the azithromycin trough concentration and positive response of neutrophils or C-reactive protein (CRP). All statistical analyses were performed using SPSS software, version 16.0 and SAS JMP software, version 13.0.
Results
Patients
During the period from November 2014 to February 2017, 52 children with LRTI who received intravenous azithromycin monotherapy were screened. There were 44 patients available for pharmacokinetic analysis after exclusion of 8 patients because of incomplete clinical information. The mean (SD) age and weight of the 44 children at the time of study were 5.25 (3.72) years and 20.98 (12.99) kg, respectively.
Measurements of azithromycin trough blood levels
The median dosage of azithromycin was 10 mg/kg (range, 7.143-12.5 mg/kg) per day in the enrolled patients. The median duration of therapy was 5.0 days. The median trough level was 0.16 mg/L (range, 0.01-0.34 mg/L).
Effectiveness assessments
Azithromycin trough concentrations were 0.25 mg/L in 36 cases (82%) and .0.25 mg/L in 8 cases (18%). A significantly higher proportion of improvement in antibacterial efficacy in terms of decreased CRP (P " 0.006) and the percentage of neutrophils (P " 0.043) was found in children with trough concentrations .0.25 mg/L compared with children with trough concentrations 0.25 mg/L (Table 2) . No significant differences were observed for other effectiveness parameters.
Safety assessments
Mild transient elevation of alanine aminotransferase adverse events was observed in two patients (4.5%) and was back to a Early target attainment of azithromycin Liu et al.
JAC
normal value after 10 days follow-up. None of the patients had a history of hepatitis and their hepatitis antibody tests were negative. There was no statistically significant difference in azithromycin trough concentration between children with liver injury and those without liver injury (P . 0.05). In addition, all children underwent an ECG (12 leads) by paediatric cardiologists, which showed that the corrected QT (QTc) intervals were normal (,440 ms) and no arrhythmias were found. No patients discontinued the azithromycin treatment due to adverse events related to gastrointestinal symptoms. No drug-related adverse events were shown to have a causal association with azithromycin therapy.
Discussion
The first 24-48 h is the prime time for success of antibiotic therapy. A previous study in adult critically ill patients had already reported that delayed antibiotic therapy had higher mortality and worse clinical outcomes, and the administration of inadequate antimicrobial treatment was most often related to bacterial antibiotic resistance. 9, 10 To the best of our knowledge, our study shows, for the first time, the clinical benefits of early target attainment for azithromycin therapy in children.
Azithromycin is used to treat a broad spectrum of bacterial infections. It should be highlighted that the choice of the 0.25 mg/L cut-off value for azithromycin trough concentrations was mainly based on our local microbiological data. Streptococcus pneumoniae, Mycoplasma pneumoniae and Haemophilus influenzae were the most common bacterial pathogens in our study and they were also the leading causes of community-acquired respiratory infections in the local hospitals. 11 However, from in vitro susceptibility data, MIC 90 is 0.25 mg/L for S. pneumoniae, M. pneumoniae and H. influenzae.
12,13
In the present study, although large inter-individual variability in trough concentrations was demonstrated, the standard treatment was well-tolerated and no liver injury or cardiovascular risk were detected. In adult patients, it has been reported that azithromycin is possibly related to arrhythmias (mainly QT interval prolongation) and risk of cardiovascular death.
14 Nevertheless, these adverse events have not been observed in paediatric patients. A recent study conducted in 86 paediatric patients in a respiratory unit also showed that QTc measurement was ,440 ms in all cases and no cases of arrhythmias were reported. 15 Long-term followup in a larger paediatric population is definitely required.
Our study had some limitations. The number of paediatric patients enrolled in the study was limited. The inclusion of patients with only azithromycin monotherapy has the following considerations: (i) for LRTI, it is still a question of whether the combination of a cephalosporin and azithromycin has more clinical benefit than azithromycin monotherapy; and (ii) the combined antimicrobial therapy might introduce additional confusing factors to interpretation of the relationship between early target attainment of azithromycin concentrations and clinical outcome. Of note, the selection of the cut-off value for azithromycin trough concentrations was mainly based on our local microbiological data. Different values might be targeted in other hospitals according to local bacterial pathogens.
In conclusion, our study showed the clinical benefits of early target attainment with azithromycin therapy in children with LRTI. Children with azithromycin trough concentrations .0.25 mg/L within the first 2 calendar days of hospitalization had a better antibacterial efficacy. Prospective trials in a large paediatric population are urgently required to confirm this observation.
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